GA-Map Dysbiosis Test Lx Publications

Check out the most recent publications featuring the GA-Map Dysbiosis Test Lx! These studies used the GA-Map Dysbiosis Test Lx to help determine how the gut microbiota takes part in various diseases such as IBS and axial spondyloarthritis. Find them below:

Irritable bowel syndrome patients who are not likely to respond tofecal microbiota transplantation.

Efficacy and Acceptability of Dietary Therapies in NonConstipated Irritable Bowel Syndrome: A Randomized Trial of Traditional Dietary Advice, the Low FODMAP Diet andthe Gluten-Free Diet.

Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis.

Principle of Analysis

The GA-map® Dysbiosis Test Lx v2 is a test that maps the intestinal microbiota profile for a selected set of bacteria. The GA-map® platform uses probes that target variable regions (V3 to V7) of the bacterial 16S rRNA gene to characterize and identify bacteria present. The targets are identified in a molecular multiplex assay that utilizes the Single Nucleotide Primer Extension (SNuPE) technology patented by Professor Knut Rudi (US6617138). A unique algorithm takes advantage of all the data generated by the detection of the SnuPE products to determine dysbiosis level in the sample. The algorithm is incorporated in the GA-map® Dysbiosis Analyzer software that accompanies the test.

If you’re looking for more publications featuring the GA-Map Dysbiosis Test Lx, find them here. If you have any questions about this test or any of our other offerings contact us here.